Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Colitis

Colitis

112

Pipeline Programs↗

216

Active Trials↗

115

Companies Involved↗

Colitis is a highly competitive landscape with 112 programs across 115 companies. 27 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

81/100

Mech. Concentration

10/100

Completion Rate

72/100

Attrition Rate

18/100

Pipeline

Programs by Phase

Preclinical37

Standard Vancomycin

Corewell Health East

Extended Vancomycin

Corewell Health East

Stool

OSF Healthcare System

Pronase

Xijing Hospital of Digestive Diseases

Nitazoxanide

Romark Laboratories L.C.

Phase 114

Loperamide

Kenvue Brands

Ursodiol

AbbVie

LIV001

Liveome Inc.

Alpha-0261

AlphaMol Science Ltd. (Shanghai)

Shr-7590

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 234

Vancomycin

Hikma Pharmaceuticals LLC

BRS201

Brigham and Women's Hospital

Aquamin

James Varani

Rifaximin

Salix

RO7837195 Matched Placebo

Roche

Phase 327

Etrasimod

Pfizer

ABX464

Abivax S.A.

Afimkibart

Roche

Encapsulated Faecal Microbiota Filtrate

Andreas Stallmach

Filgotinib

Gilead

Approved

No programs

Analysis

Modality Breakdown

88%

Small molecule

81 of 92 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 92 classified programs, each share of the total. Modality classified for 87% of 112 pipeline programs.

Analysis

Trial Status

781

clinical trials

Completed364 · 47%

Recruiting117 · 15%

Terminated106 · 14%

Unknown status61 · 8%

Active, not recruiting48 · 6%

Not yet recruiting44 · 6%

Other41 · 5%

Clinical Trials

Trial Activity

781 trials

Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04038619·40 enrolled

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting· Roche logo

Roche·Phase 1·NCT07665723·25 enrolled

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT07071519·120 enrolled

The Efficacy of Lactobacillous Probiotic and Trace Elements in the Management of Ulcerative Colitis Patients

Recruiting·NNational Hepatology & Tropical Medicine Research Institute·Approved·NCT07758335·132 enrolled

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis.

Recruiting·XXencor, Inc.·Preclinical·NCT06619990·270 enrolled

The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients

Recruiting·AAin Shams University·Preclinical·NCT07609810·60 enrolled

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07185009·751 enrolled

A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting

Recruiting· Takeda logo

Takeda·Approved·NCT06581328·200 enrolled

Fecal Microbiota Transplantation for Ulcerative Colitis Using Healthy Donors From Yunnan Dai and Han Nationalities: A Randomized Study to Screen Core Metabolites and Key Microbiota

Recruiting·FFirst Affiliated Hospital of Kunming Medical University·Phase 2·NCT07814456·200 enrolled

Microbiome-targeted Diet Therapy in Ulcerative Colitis

Recruiting·UUniversity of Minnesota·Preclinical·NCT07520461·40 enrolled

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

Recruiting·MMuhammad N Aslam, MD·Phase 2·NCT07501078·52 enrolled

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally as Single Ascending Doses With a Food-Effect Arm and Multiple Ascending Doses in Healthy Adult Participants, and as a Single Dose (Open-Label) in Patients With Active Ulcerative Colitis

Recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT07749768·90 enrolled

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07415044·1,431 enrolled

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years With Moderately to Severely Active Ulcerative Colitis

Recruiting· Roche logo

Roche·Phase 3·NCT07158242·100 enrolled

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07186101·252 enrolled

Page 1 of 53

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)